<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113193">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629667</url>
  </required_header>
  <id_info>
    <org_study_id>CD-RI-CAT-354-1066</org_study_id>
    <nct_id>NCT01629667</nct_id>
  </id_info>
  <brief_title>A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary
      function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a
      chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the effect of multiple doses of
      tralokinumab on pulmonary function in adults with mild to moderate IPF
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Percent-Predicted Forced Vital Capacity at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Mean change from baseline in percent-predicted forced vital capacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Number and percent of subjects with at least one treatment-emergent adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Disease Progression</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Number and percent of subjects who have documented disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Tralokinumab Serum Concentration</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Mean serum concentration of tralokinumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious Adverse Events</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Number and percent of subjects with at least one treatment-emergent serious adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Electrocardiogram Abnormalities</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Number and percent of subjects with at least one clinically significant electrocardiogram abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Vital Sign Abnormalities</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Number and percent of subjects with at least one clinically significant vital sign abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Number and percent of subjects with at least one clinically significant laboratory abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diffusion Capacity for Carbon Monoxide at Weeks 36, 52, and 72</measure>
    <time_frame>Weeks 36, 52, and 72</time_frame>
    <description>Mean change from baseline in percent-predicted diffusion capacity for carbon monoxide at Weeks 36, 52, and 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lung Volumes at Weeks 36, 52, and 72</measure>
    <time_frame>Weeks 36, 52, and 72</time_frame>
    <description>Mean change from baseline in lung volumes (total lung capacity, residual volume, vital capacity, functional residual capacity, and inspiratory capacity) at Weeks 36, 52, and 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Decline in the 6 Minute Walk Test</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Number and percent of subjects with a decline in the 6 Minute Walk Test greater than or equal to 50 meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Oxygen Saturation by Pulse Oximetry During the Study</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Mean change from baseline in oxygen saturation by pulse oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Exacerbations of Idiopathic Pulmonary Fibrosis</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Number and percent of subjects with at least one exacerbation of idiopathic pulmonary fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lung Function During the Study</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Mean change from baseline in lung function (forced expiratory volume in 1 second and forced vital capacity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Clinical Global Impression of Severity Scores</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Mean Clinical Global Impression of Severity scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Clinical Global Impression of Change Scores</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Mean Clinical Global Impression of Change score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Positive Antibodies to Tralokinumab</measure>
    <time_frame>Day 1 - Week 88</time_frame>
    <description>Number and percent of subjects with positive antibodies to tralokinumab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product tralokinumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product tralokinumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tralokinumab</intervention_name>
    <description>Tralokinumab is a human recombinant monoclonal antibody (MAb)) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tralokinumab</intervention_name>
    <description>Tralokinumab is a human recombinant monoclonal antibody (MAb)) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  1) IPF diagnosis for ≤ 5 years prior to Visit 1 (screening). Confirmation of
             diagnosis of IPF in accordance is required for subject inclusion 2) Confirmed
             diagnosis of IPF by clinical characteristics, HRCT and surgical lung biopsy (if
             required) 3)Mild to moderate IPF to include all of the following at screening:

               1. FVC ≥ 50% predicted normal

               2. Partial pressure of oxygen in arterial blood (PaO2) of ≥ 55 mmHg on room air or
                  50 mmHg at high altitude (&gt; 1500 meters), or oxygen saturation by pulse oximetry
                  (SpO2) of ≥ 90%on room air at rest

               3. Hemoglobin-corrected diffusion capacity for carbon monoxide (DLCO) ≥ 30%
                  predicted normal 4) Be able to walk ≥ 100 meters unassisted

        Key Exclusion Criteria:

          1. A FEV1/FVC ratio less than 0.70 at the time of screening (postbronchodilator)

          2. The extent of emphysema on the HRCT is greater than the extent of fibrosis.

          3. Currently listed for lung transplantation

          4. Use of the following medications:

               1. Immunosuppressive medications (eg, methotrexate, cyclosporine, azathioprine,
                  intramuscular long-acting depot corticosteroid) within 3 months prior to Visit 1
                  (screening). Oral prednisone ≤ 15 mg/day (or equivalent oral corticosteroid) is
                  allowed for chronic use if subject was on a stable dose at least 30 days prior
                  to Visit 1 (screening)

               2. Pirfenidone within 4 weeks prior to Visit 1 (screening)

               3. N-acetylcysteine within 4 weeks prior to Visit 1 (screening)

               4. Live attenuated vaccines within 4 weeks prior to Visit 1 (screening)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Parker, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concord</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glen Osmond</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Lambton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prahran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodville South</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cercado de Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 29, 2016</lastchanged_date>
  <firstreceived_date>June 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
